First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.

标题
First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 29, Issue 15_suppl, Pages 3006-3006
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2017-02-24
DOI
10.1200/jco.2011.29.15_suppl.3006

向作者/读者发起求助以获取更多资源

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started